What’s New in the World of Laboratory Testing: Sessions to Check Out at #2016AACC
This week marks the start of the 68th AACC Annual Scientific Meeting & Clinical Lab Expo taking place in beautiful Philly. With more than 750 exhibitors and over 200 sessions, laboratory executives from around the world will gain insight into the newest technology available to laboratories, will hear from industry thought leaders like 2016 AACC President Dr. Patricia Jones, and will have a chance to learn from peers across the healthcare continuum.
According to the AACC, attendees will benefit from “Sessions featuring world-renowned scientists to intimate brown bag sessions geared for lively discussion on hot topics, the 68th AACC Annual Scientific Meeting & Clinical Lab Expo offers something for everyone in laboratory medicine. More than 200 educational sessions in a variety of settings will give you the knowledge you need to advance professionally and develop adaptive solutions for today’s complex, challenging healthcare environment.”
4 AACC Sessions to Attend Covering Innovations in Lab Testing
Leading up to the meeting, we’d like to take this opportunity to preview of some of the changes and advancements happening in the world of laboratory testing that will be discussed at AACC this week. Whether your lab tests for toxicology, PGx, women’s health, cystic fibrosis, or genomics, these changes and innovations could impact the future of your lab.
During the AACC meeting, you’ll have opportunity to learn about the following by attending the sessions listed below (links provide further information on AACC’s website):
- Evaluation of Time-of-Flight High Resolution Mass Spectrometry for Broad Spectrum Drug Screening in Urine
In the session, “Evaluation of Time-of-Flight High Resolution Mass Spectrometry for Broad Spectrum Drug Screening in Urine“, attendees will learn that, “Urine drug screening is among the most widely used procedures in clinical/toxicology laboratories today. Immunoassays have been the frontline method used for drug screening followed by confirmation through more specific methods such as liquid chromatography coupled to unit resolution tandem mass spectrometry (LC-MS/MS). LC-MS/MS is limited by co-eluting compounds of similar structure; the fact that fragmentation does not always produce product ions; and difficulty performing non-targeted screening. Recently, high resolution mass spectrometry (HRMS) methods such as time of flight-mass spectrometry (TOF-MS) have been proposed as alternatives for non-targeted drug screening.”
- Oral Fluid in the Clinical Toxicology Laboratory: Ready for Prime Time?
In the session, “Oral Fluid in the Clinical Toxicology Laboratory: Ready for Prime Time?”, attendees will learn that “Oral fluid is increasingly being studied as a convenient alternative to urine for clinical toxicology, particularly in physician office laboratories. Urine collection is often not observed, leading to the increased potential for sample adulteration; oral fluid collection does not share that drawback. The utility of oral fluid as a viable option to urinalysis has been published. Urine drug concentrations are not representative of specific dosing regimens, but oral fluid has shown promise in the area of drug level interpretation because of its relationship to blood. Further, point-of-care tests for oral fluid are also increasingly being introduced; their limitations and advantages will be presented.”
- Laboratory Tests Related To Calcium and Bone Metabolism
In the session, “Laboratory Tests Related To Calcium and Bone Metabolism”, attendees will learn that, “In order to help clinicians with test selection and interpretation, laboratory scientists need to understand how PTH and 1,25 dihydroxyvitamin D regulate plasma calcium concentrations, and how changes in concentrations of PTH and 25-hydroxyvitamin D associate with various pathological conditions of parathyroid glands and kidneys. Furthermore, laboratorians need to be aware of the clinical utility of bone turnover markers in the treatment of osteoporosis in accordance with the recommendations from the National Osteoporosis Foundation.”
- Precision Medicine Delivered by Advances in Circulating Cell-Free DNA Diagnostics
In the session, “Precision Medicine Delivered by Advances in Circulating Cell-Free DNA Diagnostics”, attendees will learn that, “Molecular and personalized genetic tests are expanding in the routine laboratory. Circulating nucleic acids, namely extra-cellular DNA or RNA molecules present in human circulation, serve as versatile biomarkers for achieving blood-based molecular diagnostics for the investigation of fetal health, cancers, other pathologies, and post-transplantation complications. Recently, there have been some exciting advances made in relation to circulating cell-free nucleic acid analysis, resulting in cutting-edge noninvasive applications for personalized diagnostics.”
Is Your LIMS Keeping Up?
Is your lab information technology keeping up with the changes that are happening each and every day in the healthcare and technology world? It’s imperative that your lab stop and evaluate your current capabilities to ensure your lab remains competitive.
A LIMS (Laboratory Information Management System) is a critical component to any lab operation, regardless of your lab’s focus. As a lab executive, you know that a LIMS allows you to effectively manage samples and associated data to improve lab efficiency, and by using a LIMS, your lab can automate workflows, integrate instruments, and manage samples and associated information – all important aspects of a laboratory’s continued success.
Has your lab evaluated your LIMS and reporting capabilities recently? If not, it might be time for a check up.
For more information on how your lab can gain complete control, check out these recent Pathagility resources: